Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Interest Expenses (2016 - 2017)

Corcept Therapeutics (CORT) has disclosed Interest Expenses for 7 consecutive years, with $98000.0 as the latest value for Q2 2017.

  • Quarterly Interest Expenses fell 81.54% to $98000.0 in Q2 2017 from the year-ago period, while the trailing twelve-month figure was $98000.0 through Mar 2018, down 94.07% year-over-year, with the annual reading at $2.0 million for FY2016, 31.23% down from the prior year.
  • Interest Expenses hit $98000.0 in Q2 2017 for Corcept Therapeutics, down from $225000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $1.2 million in Q3 2013 to a low of $98000.0 in Q2 2017.
  • Historically, Interest Expenses has averaged $753235.3 across 5 years, with a median of $770000.0 in 2015.
  • Biggest five-year swings in Interest Expenses: skyrocketed 22720.0% in 2013 and later crashed 81.54% in 2017.
  • Year by year, Interest Expenses stood at $1.1 million in 2013, then decreased by 25.23% to $818000.0 in 2014, then decreased by 15.4% to $692000.0 in 2015, then plummeted by 40.75% to $410000.0 in 2016, then crashed by 76.1% to $98000.0 in 2017.
  • Business Quant data shows Interest Expenses for CORT at $98000.0 in Q2 2017, $225000.0 in Q1 2017, and $410000.0 in Q4 2016.